Cardiac Gene Therapy
| Autor: | Roger J. Hajjar, Antoine H. Chaanine, Jill Kalman |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Pulmonary and Respiratory Medicine
Pathology medicine.medical_specialty Genetic enhancement Genetic Vectors Disease Bioinformatics Ventricular Function Left Article Virus Immune system Animals Humans Medicine Myocytes Cardiac Heart Failure Clinical Trials as Topic Evidence-Based Medicine business.industry Molecular pathology Gene Transfer Techniques food and beverages Genetic Therapy Recovery of Function General Medicine medicine.disease Myocardial Contraction Molecular medicine Pathophysiology Treatment Outcome Heart failure Viruses Surgery Cardiology and Cardiovascular Medicine business |
| Zdroj: | Seminars in Thoracic and Cardiovascular Surgery. 22:127-139 |
| ISSN: | 1043-0679 |
| DOI: | 10.1053/j.semtcvs.2010.09.009 |
| Popis: | Heart failure is a chronic progressive disorder where frequent and recurrent hospitalizations are associated with high mortality and morbidity. The incidence and the prevalence of this disease will increase with the increase in the number of the aging population of the United States. Understanding the molecular pathology and pathophysiology of this disease will uncover novel targets and therapies that can restore the function or attenuate the damage of malfunctioning cardiomyocytes by gene therapy that becomes an interesting and a promising field for the treatment of heart failure as well as other diseases in the future. Of equal importance is developing vectors and delivery methods that can efficiently transduce the majority of the cardiomyocytes, that can offer a long term expression and that can escape the host immune response. Recombinant adeno-associated virus vectors have the potential to become a promising novel therapeutic vehicles for molecular medicine in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect